Acorda Therapeutics CEO Ron Cohen Appointed Member of Executive Committee of Biotechnology Industry Organization (BIO)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced President and CEO Ron Cohen, M.D. has been appointed to the Executive Committee of the Biotechnology Industry Organization (BIO). Dr. Cohen was also named Vice Chair of the Emerging Companies Section of BIO. BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. "BIO serves a critical role in promoting the discovery and development of new technologies in various biotechnology fields,” said Dr. Cohen. "It is a privilege to serve the organization in this new capacity and I look forward to helping BIO fulfill its mission of fostering scientific innovations that improve our healthcare, agriculture and the environment.” Acorda has been a member of BIO since 1999, and Dr. Cohen has been a member of the Emerging Companies Section since 2003. As Vice Chair, he will help to design BIO’s agenda for serving the needs of small to medium size BIO member companies, most of whom do not yet have major products approved and on the market. "Acorda’s growth from a small start-up to a fully-integrated biotechnology company with multiple products in development exemplifies how BIO members can mature and expand over time. BIO works to maintain an environment for that kind of growth by advocating for a favorable policy climate,” said James C. Greenwood, President and CEO of BIO. "We are pleased to welcome Ron to the BIO leadership team, and look forward to his continued contribution to our organization.” About Acorda Therapeutics Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda’s lead clinical product, Fampridine-SR, has completed two Phase 3 clinical trials to evaluate its safety and efficacy to improve walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the nervous system. Acorda Therapeutics, Inc. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including delays in obtaining or failure to obtain FDA approval of Fampridine-SR, the risk of unfavorable results from future studies of Fampridine-SR, Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules®, competition, failure to protect its intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from its preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.